8,134 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 8,134 shares of the company's stock, valued at approximately $248,000.

A number of other hedge funds have also modified their holdings of the company. NewEdge Advisors LLC grew its holdings in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after buying an additional 391 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares in the last quarter. Finally, R Squared Ltd bought a new position in shares of Guardant Health during the fourth quarter worth about $26,000. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. This trade represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 107,132 shares of company stock valued at $5,249,355. Insiders own 6.10% of the company's stock.

Guardant Health Trading Down 1.1%

NASDAQ:GH opened at $40.24 on Tuesday. The stock has a market cap of $4.99 billion, a P/E ratio of -11.30 and a beta of 1.49. The stock has a 50 day simple moving average of $43.75 and a 200 day simple moving average of $39.88. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.46) EPS. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research reports. UBS Group increased their price objective on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Mizuho began coverage on Guardant Health in a research note on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price target for the company. Canaccord Genuity Group raised their price target on Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. TD Securities raised their price target on Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Twenty-one investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Guardant Health currently has an average rating of "Buy" and an average target price of $52.32.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.